DGAP-News: MediClin AG: FY 2012 final results and business development
(firmenpresse) - DGAP-News: MediClin AG / Key word(s): Final Results
MediClin AG: FY 2012 final results and business development
22.03.2013 / 17:09
---------------------------------------------------------------------
High investments and a focus on areas with strong growth will secure solid
growth of Mediclin in the years to come - integrated medical care is still
an importart issue of the company's strategy
Offenburg, March 22, 2013 - The Members of the Management Board of MEDICLIN
Aktiengesellschaft (MediClin) presented a split picture at this year's
balance sheet press conference: Significantly higher Group sales and a
Group result which could not benefit from this sales increase. 'The
development of MediClin in the 2012 financial year very clearly highlights
the demand situation on the health care market and the repercussions of the
statutory regulations which aim also to keep the cost increases in the
health care sector within a manageable framework', said Frank Abele, CEO of
MediClin. He pointed out that in 2013 MediClin will continue to invest in
modification, extension und modernisation to be able to offer services that
do justice to demand. And he added: 'In 2013 some of the measures and
expansions implemented in 2012 in medical, therapeutic and nursing care
areas with strong growth will have a positive impact on sales and earnings
in the current financial year'.
MediClin rigorously pursues its corporate strategy - the provision of
cross-sector integrated medical services - by expanding its spectrum of
integrated medical services in the years ahead. The expansion of the range
of services also embraces the development of new medical, therapeutic and
nursing care concepts, which enjoy broad acceptance at cost providers and
at the market.
Summary of the Group and segment development
In 2012 Group sales amounted to EUR 509.7 mill. and were EUR 16.1 mill., or
3.3 %, higher compared to previous year's figure. The increase was achieved
by the post-acute segment and the nursing care business area. The Group
operating result was EUR 4.3 mill., EUR 8.3 mill. below last year's value.
It was burdened in 2012 by higher other operating expenses, special items
and one-time effects towards the end of the year in the range of EUR 2.8
million and higher staff costs. The Group result accounts for EUR -1.5
mill. (2011: EUR 3.1 mill.).
In 2012 the rise in sales in the post-acute segment and in the nursing care
business area can be attributed to a significant increase in occupancy
compared with the previous year and to the broader range of medical and
nursing care services. In the acute segment, sales in the 2012 financial
year were lower than in the previous year in spite of the increase in cases
and the greater number of nursing days. One of the reasons was the shift in
the product mix, and another reason was the restructuring measures to
introduce new treatment concepts in a number of hospitals which adversely
affected sales. The available capacities could not be fully exhausted in
2012. Sales from outpatient healthcare services, including services of the
medical care centres, increased in 2012. Their share in Group sales is 3.3
% (previous year: 3.2 %).
The result in the post-acute segment declined by EUR 0.2 mill. to EUR 2.6
mill. despite the positive sales development due to higher costs. The acute
segment result fell during the reporting year by EUR 8.3 mill. to EUR 7.2
mill. In the courseof the financial year, bed capacity in the acute
segment was raised in a total of four facilities. The newly created
capacities are being successively occupied. In the years ahead, the
occupancy rate of these additional capacities is expected to rise.
In 2012 about 2.6 million nursing days were provided and 121 thousand cases
were treated. The occupancy in the Group was 86.3 %, significantly above
previous year's value (2011: 84.8%).
The average number of employees in 2012, calculated on the basis of
full-time staff, was 6,256 (previous year: 6,099 full-time staff).
A total of EUR 27.3 mill. were invested (2011: EUR 29.9 mill.). Cash and
cash equivalents amounted to EUR 16.2 mill. (2011: EUR 15.6 mill.).
Capacity expansions will be pushed in areas of strong demand
The capacity expansion proposed or already realized primarily concerns the
medical specialist fields of psychiatry, psychosomatics and neurology. But
growth potential can also be noted in the orthopaedics and nursing care
areas as well as in specialist themes. Therefore, in the fiscal year 2013,
MediClin will also focus on transforming and expanding existing capacities.
By making this capital expenditure, MediClin aims to bolster the
significance of its hospitals at their particular locations and to generate
internal growth. Market potential exists for this.
A further important area of activity in 2013 will be the continuous
assessment of medical and therapeutic workflow and operating processes. In
the meantime, MediClin has achieved a high standard of measurability and
verifiability in terms of the quality of its results. MediClin keeps to the
goal of translating the insight thus derived into better and more
innovative treatment and therapy concepts.
Outlook
The Management Board forecasts a slight sales gain in 2013 and expects a
group operating result, excluding one-off and special effects, at the same
level as the previous year's result - provided there is no material change
in the referral behaviour of the coverage providers in 2013 and the
situation of the industry is not adversely affected by new statutory
regulations.
About MediClin AG (Ticker: MED; WKN: 659 510)
MediClin AG is a nation-wide clinic operator and large provider of services
in the area of Psycho- and Neuro-sciences as well as Orthopaedic. With 34
clinics and 7 nursing care facilities and 11 Medizinische
Versorgungszentren (medical care units) in 11 federal states MediClin has a
total capacity of approximately 8,100 beds. MediClins' facilities include
acute care clinics, i.e., general hospitals, special treatment facilities,
specialised hospitals and clinics for post-acute treatment and medical
rehabilitation. MediClin has approximately 8,500 employees.
Important notice:
This press release includes future-oriented statements which are based on
assumptions and estimates. While MediClin AG is of the opinion that these
assumptions and estimates are correct, the actual future developments and
actual future results may deviate from these assumptions and estimates due
to the impact of various factors such as changes in the economic conditions
in Germany, legal changes concerning the health system, changes relating to
cost providers' expense behaviour. MediClin does not assume liability and
gives no warranty that future developments and the income actually achieved
in the future will comply with the assumptions and estimates stated in this
press release.
End of Corporate News
---------------------------------------------------------------------
22.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MediClin AGOkenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-189
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr(at)mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
204950 22.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2013 - 17:09 Uhr
Sprache: Deutsch
News-ID 242357
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 265 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MediClin AG: FY 2012 final results and business development"
steht unter der journalistisch-redaktionellen Verantwortung von
MediClin AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
